These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 32538234)

  • 41. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
    Kaide CG; Gulseth MP
    J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
    Terayama Y
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1171-1181. PubMed ID: 28169097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.
    Adcock DM; Gosselin R
    Thromb Res; 2015 Jul; 136(1):7-12. PubMed ID: 25981138
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
    Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
    J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer.
    Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T
    J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An update on laboratory assessment for direct oral anticoagulants (DOACs).
    Gosselin RC; Adcock DM; Douxfils J
    Int J Lab Hematol; 2019 May; 41 Suppl 1():33-39. PubMed ID: 31069969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. When do patients prefer a direct oral anticoagulant over a vitamin K antagonist?
    Boom MS; Berghuis EM; Nieuwkerk PT; Pinedo S; Büller HR
    Neth J Med; 2015 Oct; 73(8):368-72. PubMed ID: 26478546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Managing the perioperative patient on direct oral anticoagulants.
    Leitch J; van Vlymen J
    Can J Anaesth; 2017 Jun; 64(6):656-672. PubMed ID: 28429198
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors.
    Favaloro EJ; Lippi G
    Semin Thromb Hemost; 2015 Mar; 41(2):208-27. PubMed ID: 25703514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute subdural hematoma in patients on oral anticoagulant therapy: management and outcome.
    Won SY; Dubinski D; Bruder M; Cattani A; Seifert V; Konczalla J
    Neurosurg Focus; 2017 Nov; 43(5):E12. PubMed ID: 29088960
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants.
    Rosovsky R; Merli G
    Tech Vasc Interv Radiol; 2017 Sep; 20(3):141-151. PubMed ID: 29029708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding.
    Xu Y; Schulman S; Dowlatshahi D; Holbrook AM; Simpson CS; Shepherd LE; Wells PS; Giulivi A; Gomes T; Mamdani M; Frymire E; Khan S; Johnson AP;
    Thromb Res; 2019 Oct; 182():12-19. PubMed ID: 31434018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation.
    Fernández CS; Gullón A; Formiga F
    J Comp Eff Res; 2020 May; 9(7):509-523. PubMed ID: 32329353
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of bleeding in patients receiving direct oral anticoagulants.
    Hellenbart EL; Faulkenberg KD; Finks SW
    Vasc Health Risk Manag; 2017; 13():325-342. PubMed ID: 28860793
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS).
    Perlman A; Wanounou M; Goldstein R; Choshen Cohen L; Singer DE; Muszkat M
    CNS Drugs; 2019 Dec; 33(12):1223-1228. PubMed ID: 31686406
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors Associated With the Choice of Oral Anticoagulant Class in the Older Patients: An Observational Study.
    Pagès A; Sabatier R; Sallerin B
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):332-337. PubMed ID: 32266832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio.
    Bernier M; Lancrerot SL; Parassol N; Lavrut T; Viotti J; Rocher F; Drici MD
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):472-477. PubMed ID: 33030858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.